• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

循环微小RNA作为犬类心脏病新型生物标志物的鉴定与特征分析

Identification and Characterization of Circulating MicroRNAs as Novel Biomarkers in Dogs With Heart Diseases.

作者信息

Ro Woong-Bin, Kang Min-Hee, Song Doo-Won, Kim Heyong-Seok, Lee Ga-Won, Park Hee-Myung

机构信息

Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, South Korea.

出版信息

Front Vet Sci. 2021 Oct 11;8:729929. doi: 10.3389/fvets.2021.729929. eCollection 2021.

DOI:10.3389/fvets.2021.729929
PMID:34708100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8542680/
Abstract

Previous studies in humans have confirmed dysregulations of circulating microRNAs (miRNAs) in patients with various cardiovascular diseases. However, studies on circulating miRNAs in dogs with various heart diseases are limited in number. This study aimed to identify significantly dysregulated circulating miRNAs and characterize them as novel biomarkers in dogs with heart diseases. Circulating levels of 11 miRNAs were investigated in serum samples of 82 dogs (72 with heart diseases and 10 healthy dogs) using quantitative reverse transcription-polymerase chain reaction. The results were correlated to clinical data including echocardiographic results and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels. Upregulation of cfa-miR-130b was observed in dogs with myxomatous mitral valve degeneration (MMVD) stage B, patent ductus arteriosus, and pulmonic stenosis. In dogs with MMVD stage B, cfa-miR-130b was upregulated and correlated with clinical indices. In receiver operating characteristic (ROC) analysis, cfa-miR-130b accurately distinguished dogs with diseases from healthy dogs. We also observed that cfa-miR-375 and cfa-let-7b were upregulated in dogs with concentric cardiac hypertrophy. The cfa-miR-375 was correlated with concentric hypertrophy indices and was an accurate indicator of concentric hypertrophy in ROC analysis. The miRNAs identified in this study may be used as novel biomarkers and possible candidates for therapeutic targets in various canine heart diseases.

摘要

先前针对人类的研究已证实，患有各种心血管疾病的患者体内循环微RNA（miRNA）存在失调。然而，关于患有各种心脏病的犬类体内循环miRNA的研究数量有限。本研究旨在识别显著失调的循环miRNA，并将其表征为患有心脏病犬类的新型生物标志物。使用定量逆转录-聚合酶链反应，对82只犬（72只患有心脏病，10只健康犬）的血清样本中11种miRNA的循环水平进行了研究。研究结果与包括超声心动图结果和N端前B型利钠肽（NT-proBNP）水平在内的临床数据相关。在患有黏液瘤性二尖瓣退化（MMVD）B期、动脉导管未闭和肺动脉狭窄的犬类中，观察到cfa-miR-130b上调。在患有MMVD B期的犬类中，cfa-miR-130b上调且与临床指标相关。在受试者工作特征（ROC）分析中，cfa-miR-130b能准确区分患病犬和健康犬。我们还观察到，在患有同心性心肌肥大的犬类中，cfa-miR-375和cfa-let-7b上调。cfa-miR-375与同心性肥大指标相关，并且在ROC分析中是同心性肥大的准确指标。本研究中鉴定出的miRNA可作为新型生物标志物以及各种犬类心脏病治疗靶点的潜在候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/4adf6744a83f/fvets-08-729929-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/ebb44dd1cc3d/fvets-08-729929-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/f3bcf7c1e1ca/fvets-08-729929-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/bb58b02de065/fvets-08-729929-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/8f342e9e29fb/fvets-08-729929-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/e9746c1636f4/fvets-08-729929-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/0311ff26b88e/fvets-08-729929-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/826e51ff1eb0/fvets-08-729929-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/4adf6744a83f/fvets-08-729929-g0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/ebb44dd1cc3d/fvets-08-729929-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/f3bcf7c1e1ca/fvets-08-729929-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/bb58b02de065/fvets-08-729929-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/8f342e9e29fb/fvets-08-729929-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/e9746c1636f4/fvets-08-729929-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/0311ff26b88e/fvets-08-729929-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/826e51ff1eb0/fvets-08-729929-g0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6de3/8542680/4adf6744a83f/fvets-08-729929-g0008.jpg

相似文献

1
Identification and Characterization of Circulating MicroRNAs as Novel Biomarkers in Dogs With Heart Diseases.循环微小RNA作为犬类心脏病新型生物标志物的鉴定与特征分析
Front Vet Sci. 2021 Oct 11;8:729929. doi: 10.3389/fvets.2021.729929. eCollection 2021.
2
Expression Profile of Circulating MicroRNAs in Dogs With Cardiac Hypertrophy: A Pilot Study.患有心脏肥大的犬类循环微RNA的表达谱：一项初步研究。
Front Vet Sci. 2021 Apr 9;8:652224. doi: 10.3389/fvets.2021.652224. eCollection 2021.
3
Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease.犬黏液瘤样二尖瓣疾病中循环微小RNA的表达谱分析
Int J Mol Sci. 2015 Jun 19;16(6):14098-108. doi: 10.3390/ijms160614098.
4
Genome-wide sequencing and quantification of circulating microRNAs for dogs with congestive heart failure secondary to myxomatous mitral valve degeneration.对患有黏液瘤性二尖瓣变性继发充血性心力衰竭的犬进行全基因组测序及循环微RNA定量分析。
Am J Vet Res. 2018 Feb;79(2):163-169. doi: 10.2460/ajvr.79.2.163.
5
Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.N端前心钠素与三种心脏生物标志物对黏液瘤样二尖瓣疾病犬临床分期鉴别能力的比较。
J Vet Med Sci. 2021 Apr 24;83(4):705-715. doi: 10.1292/jvms.20-0629. Epub 2021 Feb 5.
6
Circulating Galectin-3 Evaluation in Dogs With Cardiac and Non-cardiac Diseases.患有心脏疾病和非心脏疾病犬类的循环半乳糖凝集素-3评估
Front Vet Sci. 2021 Oct 14;8:741210. doi: 10.3389/fvets.2021.741210. eCollection 2021.
7
Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model.在自然发生的犬类模型中，循环外泌体微小RNA与黏液瘤样二尖瓣疾病继发的心力衰竭相关。
J Extracell Vesicles. 2017 Jul 12;6(1):1350088. doi: 10.1080/20013078.2017.1350088. eCollection 2017.
8
Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.血浆人胰岛素作为犬黏液瘤性二尖瓣疾病的预后生物标志物：与血浆N末端脑钠肽前体的比较
Pol J Vet Sci. 2018 Dec;21(4):673-680. doi: 10.24425/124305.
9
The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.NT-proBNP和proANP 31 - 67检测在犬黏液瘤性二尖瓣疾病分期中的诊断相关性。
Vet Clin Pathol. 2013 Jun;42(2):196-206. doi: 10.1111/vcp.12044. Epub 2013 Apr 24.
10
The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.在DELAY研究中，临床、影像学、超声心动图变量及心脏生物标志物对评估患有临床前期黏液瘤性二尖瓣疾病的犬发生心力衰竭或心源性死亡风险的预测价值。
J Vet Cardiol. 2021 Aug;36:77-88. doi: 10.1016/j.jvc.2021.04.009. Epub 2021 May 16.

引用本文的文献

1
Involvement of TGF-β, mTOR, and inflammatory mediators in aging alterations during myxomatous mitral valve disease in a canine model.犬粘液瘤样二尖瓣疾病衰老改变中转化生长因子-β、雷帕霉素靶蛋白及炎症介质的作用
Geroscience. 2025 Jan 27. doi: 10.1007/s11357-025-01520-0.
2
Assessing the use of blood microRNA expression patterns for predictive diagnosis of myxomatous mitral valve disease in dogs.评估血液中微小RNA表达模式用于犬黏液瘤样二尖瓣疾病预测诊断的应用。
Front Vet Sci. 2024 Nov 1;11:1443847. doi: 10.3389/fvets.2024.1443847. eCollection 2024.
3
Adipose-derived stem cell exosomes act as delivery vehicles of microRNAs in a dog model of chronic hepatitis.

本文引用的文献

1
Overexpression of miR-375 Protects Cardiomyocyte Injury following Hypoxic-Reoxygenation Injury.miR-375 的过表达可保护心肌细胞免受缺氧/复氧损伤。
Oxid Med Cell Longev. 2020 Jan 3;2020:7164069. doi: 10.1155/2020/7164069. eCollection 2020.
2
Circulating miR-130 and its target PPAR-γ may be potential biomarkers in patients of coronary artery disease with type 2 diabetes mellitus.循环 miR-130 及其靶标 PPAR-γ 可能是 2 型糖尿病合并冠心病患者的潜在生物标志物。
Mol Genet Genomic Med. 2019 Sep;7(9):e909. doi: 10.1002/mgg3.909. Epub 2019 Aug 1.
3
ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.
脂肪干细胞外泌体在慢性肝炎犬模型中作为 microRNAs 的递药载体。
Nanotheranostics. 2024 Mar 9;8(3):298-311. doi: 10.7150/ntno.93064. eCollection 2024.
4
Unique miRomics Expression Profiles in -Infected Mandibles during Periodontitis Using Machine Learning.基于机器学习的牙周炎感染下颌骨中独特的 miRomics 表达谱。
Int J Mol Sci. 2023 Nov 16;24(22):16393. doi: 10.3390/ijms242216393.
5
A review on microRNA detection and expression studies in dogs.犬类微小RNA检测与表达研究综述
Front Vet Sci. 2023 Oct 5;10:1261085. doi: 10.3389/fvets.2023.1261085. eCollection 2023.
6
Plasma small extracellular vesicles from dogs affected by cutaneous mast cell tumors deliver high levels of miR-21-5p.患有皮肤肥大细胞瘤的犬血浆中的小细胞外囊泡携带高水平的miR-21-5p。
Front Vet Sci. 2023 Jan 10;9:1083174. doi: 10.3389/fvets.2022.1083174. eCollection 2022.
7
Prospective pilot study on the predictive significance of plasma miR-30b-5p through the study of echocardiographic modifications in Cavalier King Charles Spaniels affected by different stages of myxomatous mitral valve disease: The PRIME study.前瞻性初步研究通过超声心动图改变研究不同阶段黏液样二尖瓣疾病对查理王小猎犬血浆 miR-30b-5p 的预测意义：PRIME 研究。
PLoS One. 2022 Dec 27;17(12):e0274724. doi: 10.1371/journal.pone.0274724. eCollection 2022.
8
Emerging Roles of Micrornas in Veterinary Cardiology.微小RNA在兽医心脏病学中的新作用
Vet Sci. 2022 Sep 28;9(10):533. doi: 10.3390/vetsci9100533.
9
Systematic analysis of different degrees of haemolysis on miRNA levels in serum and serum-derived extracellular vesicles from dogs.系统分析不同程度溶血对犬血清和血清衍生细胞外囊泡中 miRNA 水平的影响。
BMC Vet Res. 2022 Sep 22;18(1):355. doi: 10.1186/s12917-022-03445-8.
10
Circulating MiR-30b-5p is upregulated in Cavalier King Charles Spaniels affected by early myxomatous mitral valve disease.循环 miR-30b-5p 在患有早期黏液样二尖瓣疾病的骑士查理王小猎犬中上调。
PLoS One. 2022 Jul 11;17(7):e0266208. doi: 10.1371/journal.pone.0266208. eCollection 2022.
ACVIM 共识指南：犬黏液瘤性二尖瓣疾病的诊断与治疗。
J Vet Intern Med. 2019 May;33(3):1127-1140. doi: 10.1111/jvim.15488. Epub 2019 Apr 11.
4
miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges.miRNAs 在心血管疾病中的作用：潜在的生物标志物、治疗靶点及挑战
Acta Pharmacol Sin. 2018 Jul;39(7):1073-1084. doi: 10.1038/aps.2018.30. Epub 2018 Jun 7.
5
miR-130 aggravates acute myocardial infarction-induced myocardial injury by targeting PPAR-γ.miR-130 通过靶向 PPAR-γ 加重急性心肌梗死引起的心肌损伤。
J Cell Biochem. 2018 Sep;119(9):7235-7244. doi: 10.1002/jcb.26903. Epub 2018 May 15.
6
Genome-wide sequencing and quantification of circulating microRNAs for dogs with congestive heart failure secondary to myxomatous mitral valve degeneration.对患有黏液瘤性二尖瓣变性继发充血性心力衰竭的犬进行全基因组测序及循环微RNA定量分析。
Am J Vet Res. 2018 Feb;79(2):163-169. doi: 10.2460/ajvr.79.2.163.
7
Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women?性别与心血管疾病：性别偏倚的 microRNA 网络是否是女性射血分数保留型心力衰竭的驱动因素？
Cardiovasc Res. 2018 Feb 1;114(2):210-225. doi: 10.1093/cvr/cvx223.
8
MicroRNA as a Therapeutic Target in Cardiac Remodeling.MicroRNA 作为心脏重构治疗靶点。
Biomed Res Int. 2017;2017:1278436. doi: 10.1155/2017/1278436. Epub 2017 Sep 28.
9
Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model.在自然发生的犬类模型中，循环外泌体微小RNA与黏液瘤样二尖瓣疾病继发的心力衰竭相关。
J Extracell Vesicles. 2017 Jul 12;6(1):1350088. doi: 10.1080/20013078.2017.1350088. eCollection 2017.
10
Therapeutic inhibition of miR-375 attenuates post-myocardial infarction inflammatory response and left ventricular dysfunction via PDK-1-AKT signalling axis.治疗性抑制 miR-375 通过 PDK-1-AKT 信号通路减轻心肌梗死后炎症反应和左心室功能障碍。
Cardiovasc Res. 2017 Jul 1;113(8):938-949. doi: 10.1093/cvr/cvx052.